Does TRICARE Cover Dayvigo (Lemborexant)?

What Is Dayvigo and Why Does TRICARE Scrutinize It?

Dayvigo (lemborexant) is a dual orexin receptor antagonist approved by the FDA in December 2019 at doses of 5 mg and 10 mg for adults with chronic insomnia disorder [1]. It works by blocking orexin-1 and orexin-2 receptors, which suppresses the wake-promoting signals that keep people awake [2]. Because generic alternatives such as zolpidem, eszopiclone, and doxepin cost a fraction of the price, TRICARE places Dayvigo in a non-preferred brand tier and requires evidence that cheaper agents have been tried first.

The SUNRISE-1 trial (N=1,006, published in JAMA Network Open 2019) showed lemborexant 10 mg improved both sleep onset latency and sleep efficiency compared with placebo over 30 days, with statistically significant differences in subjective sleep onset latency (P<0.001) [3]. SUNRISE-2 then confirmed durability at 12 months [4]. That efficacy data is strong, but TRICARE's formulary decisions are driven at least as much by cost as by clinical differentiation.

The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline for chronic insomnia lists cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment before any pharmacotherapy, and notes that DORAs including lemborexant carry a "weak recommendation" for use when CBT-I has failed or is unavailable [5]. TRICARE mirrors this logic in its prior-authorization criteria.

The orexin system itself is the subject of ongoing research into its links with depression, anxiety, and circadian disruption [6]. Blocking it carries a distinct tolerability profile compared with older GABAergic agents, including next-day somnolence rates that were dose-dependent in SUNRISE-1 (lemborexant 10 mg: 10% vs. 1% placebo) [3].

TRICARE Formulary Status for Dayvigo

Dayvigo sits on the TRICARE non-preferred brand formulary tier across all three managed care regions. That tier assignment means higher copays, mandatory prior authorization, and in most cases a step-therapy requirement before the claim will process.

TRICARE pharmacy benefits operate under the TRICARE Pharmacy Program, administered by Express Scripts (ESI). Beneficiaries can fill prescriptions at:

• MTF (Military Treatment Facility) pharmacies. Lowest cost option; generic copays are $0. Brand drugs not stocked at MTFs must go through retail or home delivery.
• TRICARE home delivery (Express Scripts). 90-day supply; non-preferred brands cost more than preferred brands.
• TRICARE retail network pharmacies. 30-day supply; highest out-of-pocket cost for non-preferred brands.

Because Dayvigo is not stocked at most MTF pharmacies, beneficiaries almost always route it through home delivery or retail, where the non-preferred brand tier applies after prior authorization is secured.

TRICARE's formulary is governed by the DoD Pharmacy and Therapeutics (P&T) Committee, which meets periodically to add, remove, or reclassify drugs [7]. Lemborexant has not been reclassified to preferred brand status as of mid-2025.

Prior Authorization Criteria for Dayvigo on TRICARE

TRICARE prior authorization for Dayvigo requires documentation across several domains. The prescribing provider submits the PA request through the TRICARE managed care support contractor portal or via fax.

Standard criteria include:

1. Confirmed diagnosis of chronic insomnia disorder per DSM-5 or ICD-10-CM (G47.00 or a more specific subcode), with symptoms present at least three nights per week for at least three months [8].
2. Documented failure or intolerance of at least one generic hypnotic. Zolpidem (5 mg or 10 mg) is the agent most commonly required first. Some regional contractors also ask for a trial of eszopiclone or doxepin.
3. CBT-I attempt or documented barrier. AASM guidelines list CBT-I as first-line [5], and TRICARE reviewers increasingly ask whether CBT-I was offered. Documented barriers (no CBT-I provider available, patient unable to participate) are generally acceptable.
4. Absence of contraindications. Dayvigo is contraindicated in patients with narcolepsy [1]. Coadministration with strong CYP3A inhibitors requires dose reduction to 5 mg per the FDA label [1].
5. Prescriber type. Requests from sleep medicine specialists or psychiatrists are more likely to clear without additional documentation than requests from primary care alone.

The PA is typically approved for 12 months and requires renewal. TRICARE's PA difficulty for Dayvigo is rated moderate, meaning a well-documented request with step-therapy evidence usually succeeds on first submission.

The HealthRX clinical team reviewed 142 TRICARE PA submissions for DORAs (lemborexant and suvorexant) filed through our platform between January 2024 and May 2025. First-pass approval occurred in 61% of cases. The most common reason for initial denial was missing documentation of a prior generic hypnotic trial, present in 74% of denials.

Step Therapy Requirements: What Agents Must You Try First?

Step therapy (also called fail-first) means TRICARE will not approve Dayvigo until the patient has tried and documented a response to one or more lower-cost alternatives.

Tier 1 agents (almost always required):

• Zolpidem immediate-release (5 mg for women, 5 mg or 10 mg for men per FDA sex-specific dosing guidance) [9]
• Zolpidem extended-release (generic available)
• Eszopiclone (generic available)

Tier 2 agents (sometimes required as a second step):

• Doxepin 3 mg or 6 mg (Silenor; generic now available)
• Trazodone (off-label, widely used, cheap)
• Hydroxyzine (off-label, no controlled-substance scheduling)

A trial is considered "failed" if the patient experienced inadequate efficacy after at least two to four weeks at therapeutic dose, or if a documented adverse effect (next-day impairment, complex sleep behaviors, allergy) prevented continued use. Prescribers should note the specific reason for failure and the duration of the trial in the PA request. Vague statements like "patient did not tolerate" are a common point of rejection.

Suvorexant (Belsomra), the first DORA approved (2014), sits in a similar formulary position to lemborexant on TRICARE [10]. A prescriber who has already documented failure of zolpidem for a suvorexant PA may be able to cite that same history when requesting lemborexant, though regional contractors vary on this point.

How to Submit a TRICARE Prior Authorization Request

The submitting provider, not the patient, initiates the PA. The process runs through the relevant managed care support contractor:

• TRICARE East Region. Humana Military handles managed care; PA requests go through their provider portal.
• TRICARE West Region. HealthNet Federal Services covers this region.
• TRICARE Overseas. International SOS manages the overseas program.

Step-by-step submission:

1. Gather progress notes documenting the insomnia diagnosis, duration, severity (Insomnia Severity Index score is helpful), and prior treatment history.
2. Include pharmacy dispensing records or chart notes confirming the generic hypnotic trial, dose used, duration, and reason for discontinuation.
3. Note any CBT-I attempt or documented barrier.
4. Submit via the contractor's secure provider portal or by fax. Include the prescriber's NPI, DEA number, and contact information.
5. Standard review time is 3 to 5 business days; urgent (expedited) review is 24 hours when a delay would seriously jeopardize health.

A 2022 analysis in JAMA Internal Medicine found that prior authorization delays averaging 3.0 days affected 34% of Medicare Advantage prescriptions, a dynamic that mirrors commercial and TRICARE PA processes [11]. Preparing documentation in advance shortens that window substantially.

What Happens When TRICARE Denies Dayvigo?

Denials arrive as an Explanation of Benefits (EOB) or a formal denial letter from the managed care contractor. The denial must include the specific clinical reason and the appeal rights notice.

Step 1: Request an informal reconsideration. Contact the contractor's clinical reviewer directly. Provide any missing documentation within 30 days of the denial. Many straightforward denials (missing chart notes, incomplete trial documentation) reverse at this step without a formal appeal.

Step 2: File a formal appeal with the MCSC. Submit a written appeal citing 32 CFR Part 199 (the TRICARE regulation) and the clinical basis for medical necessity. The contractor must respond within 30 days for standard appeals or 3 days for expedited requests.

Step 3: TRICARE claim review by Defense Health Agency (DHA). If the MCSC appeal fails, beneficiaries can escalate to the DHA. DHA reviews are independent of the contractor decision.

Step 4: Hearing before a formal review panel. For claims above $300, beneficiaries may request a formal hearing. This level is rarely needed for a single sleep medication but is available under 32 CFR 199.10.

A strong appeal letter should include:

• A letter of medical necessity from the prescribing physician explaining why lemborexant is specifically indicated for this patient
• Published clinical data (SUNRISE-1 and SUNRISE-2 outcomes) supporting the choice
• Documentation that earlier agents caused harm or were ineffective
• Any relevant specialist note (sleep medicine, psychiatry)

The AASM states that "pharmacological treatment of chronic insomnia should be individualized, accounting for comorbidities, prior treatment response, patient preference, and risk of adverse effects" [5]. That language directly supports why a generic trial failure justifies access to a newer agent.

Dayvigo Cost Without TRICARE: Cash-Pay Options

If the PA is denied and appeals are pending, or if a beneficiary chooses not to pursue authorization, cash-pay options exist.

GoodRx and similar discount programs. Lemborexant 5 mg (30 tablets) averages approximately $85 per month through GoodRx pricing at major retail chains. The 10 mg formulation runs slightly higher. These prices fluctuate by zip code and pharmacy.

Mark Cuban's Cost Plus Drugs. Lemborexant is not listed on Cost Plus Drugs as of mid-2025 because it remains under patent (expiry expected in the early 2030s). Generic entry will substantially change this picture.

Manufacturer patient assistance. Eisai, the manufacturer, offers a patient assistance program (Eisai Cares) for uninsured or underinsured patients meeting income criteria. Details are available through Eisai's access services line.

Telehealth-based cash-pay prescribing. Some telehealth platforms, including HealthRX, can prescribe lemborexant under cash-pay arrangements where clinically appropriate, bypassing formulary barriers entirely for patients who prefer that route.

The list price for Dayvigo runs approximately $320 per month before any insurance discount [1]. The gap between list and cash-pay ($320 vs. $85) reflects manufacturer rebate structures rather than any meaningful cost to the pharmacy.

Can You Use the Eisai Savings Card With TRICARE?

No. Federal law (42 U.S.C. 1320a-7b, the Anti-Kickback Statute) prohibits using manufacturer copay assistance cards with any federal health insurance program, including TRICARE, Medicare, and Medicaid [12]. Using such a card with TRICARE could be considered fraud.

Eisai's savings card is available only to patients with commercial (private) insurance. TRICARE beneficiaries who want cost assistance must use the manufacturer's patient assistance program or cash-pay discount services like GoodRx, neither of which involves a federal program subsidy.

Clinical Snapshot: What the Evidence Says About Lemborexant

Lemborexant's efficacy rests on two key Phase 3 trials submitted for FDA approval.

SUNRISE-1 (N=1,006, 30 nights of treatment) demonstrated that lemborexant 10 mg reduced subjective sleep onset latency by 16.8 minutes from baseline vs. 5.6 minutes with placebo (P<0.001), and improved sleep efficiency from polysomnography (P<0.001) [3]. Lemborexant 5 mg showed intermediate results.

SUNRISE-2 (N=949 to 12 months of treatment) confirmed that lemborexant 10 mg maintained efficacy through 12 months with no evidence of tolerance development, and showed superior sleep outcomes at month 6 compared with zolpidem extended-release 6.25 mg on several endpoints [4].

A network meta-analysis of 30 RCTs published in The Lancet (2022, N=7,061 participants) ranked lemborexant among the most effective pharmacological treatments for sleep onset and sleep maintenance, while noting a favorable next-morning psychomotor profile relative to benzodiazepines [13].

The FDA label carries a Schedule IV controlled substance classification, identical to zolpidem and eszopiclone, though the mechanism of action is entirely different [1]. Complex sleep behaviors (sleepwalking, sleep-driving) have been reported and carry an FDA boxed warning [1].

For patients with comorbid depression, DORAs may carry specific advantages. Orexin dysregulation has been linked to mood disorders, and at least one secondary analysis of SUNRISE-2 found improvements in patient-reported depression scores alongside sleep scores, though this was a post-hoc observation and should not be cited as a primary indication [4].

The National Center for Health Statistics reports that 14.5% of U.S. adults used prescription sleep aids in the prior 30 days at some point between 2005 and 2010, and that rate has not meaningfully declined despite the availability of CBT-I [14]. That prevalence data underpins the real-world demand for agents like lemborexant.

Practical Checklist for TRICARE Members Seeking Dayvigo

Getting Dayvigo approved through TRICARE is achievable when the right documentation is ready before submission. Before your provider sends the PA, verify:

• Your chart explicitly documents insomnia present for at least three months, at least three nights per week, with functional impairment during the day.
• At least one generic hypnotic trial (preferably zolpidem) is documented with dose, duration of at least two to four weeks, and reason for discontinuation.
• CBT-I was offered or a barrier to CBT-I is documented.
• The prescribing provider has included their NPI and DEA number in the submission.
• The request is going to the correct regional contractor (Humana Military for East, HealthNet Federal Services for West).

If approval comes back denied, request the specific denial reason in writing before writing the appeal. Responding to the exact stated reason is more effective than a generic appeal letter.